Abstract We investigated whether SPARCL1 played an essential role in tumor initiation, formation and progression of colorectal carcinomas. In this study, we examined expression of SPARCL1 protein in the normal colorectal mucosa, adjacent normal mucosa and primary and lymph node metastases from colorectal cancer patients. In matched patients, we found that SPARCL1 was negative in the distant normal colorectal mucosa, weakly expressed in the adjacent normal mucosa, strongly expressed in primary colorectal adenocarcinomas and slightly expressed in their lymph node metastases. A similar pattern was observed in the SPARCL1 expression from our series of non-matched colorectal cancer patients. The strongest expression and highest frequency of the SPARCL1 protein were found in the primary cancers. Interestingly, in the primary tumors, the frequency of SPARCL1 expression was significantly increased from the Dukes' A to Dukes' B tumors and then decreased gradually from the Dukes' B to C and D tumors. There was no difference in the intensity of SPARCL1 expression between the central areas and invasion margins of the primary tumors. Moreover, the SPARCL1 protein was more strongly expressed in the highly differentiated tumors than the lower differentiated ones. The patients with positive expression of SPARCL1 in their tumors had worse prognosis than the patients with SPARCL1-negative ones, even after the analyses by Multivariate and Interaction method. Expression of SPARCL1 protein might be a valuable biomarker for early diagnosis in colorectal cancers and further predicting patients' prognosis.
Background
Colorectal cancer is one of the most common types of cancers worldwide with poor prognosis. There are more than 1 million individuals who develop colorectal cancer every year [1] . The disease-specific mortality is near one third in the developed countries, although new therapeutic techniques for better treatment of the colorectal cancer patients have been introduced to the clinics during the last decades. Therefore, it appears to be important to search for molecular biomarkers for carcinogenesis, early tumor diagnosis, better treatments and prognosis in colorectal cancers.
Colorectal cancers have been regarded as phenotypes resulting from different genetic accumulations of various genetic alterations, which lead to the malignant characteristics of uncontrolled cell growth, tumor cell invasiveness and further distant metastasis. Recent molecular biology studies on colorectal cancer have increased our understanding of the genetics of colorectal cancer [2] .
Secreted Protein Acidic and Rich in Cysteine (SPARC) has been shown to be involved in many physiological functions in cell biology, such as cellular adhesion [3] , cell proliferation [4] , cell shape modulation, cell cycle inhibition, synthesis of extracellular matrix and also function by interaction with extracellular matrix proteins and growth factors. In an animal study, SPARC-knockout mice suffered from cataracts due to aberrations in the composition and structure of extracellular matrix [5] . Moreover, SPARC has been over-expressed in many cancer types, such as colon and liver cancers, and has been speculated as a potential gene involved in cancer formation and progression [6, 7] . SPARC has been associated with cancer chemotherapy in colon cancer, and the expression of SPARC has been decreased after the cancer chemotherapy [8, 9] .
There are ten protein members in the SPARC family, with the present study concentrating on SPARC-like protein 1 (SPARCL1 or Hevin). SPARCL1 gene is localized at chromosome 4q22 and has been conserved in humans. SPARCL1 is widely expressed in normal and cancer tissues, and it was initially identified as an anti-adhesive extracellular matrix protein with anti-proliferative effects mediated through cell-cell adhesion [10, 11] . Down-regulation of SPARCL1 has been found in several tumor types such as pancreatic, prostate, bladder, ovarian, breast and non-small cell lung cancers, and this suggests that SPARCL1 may be a candidate for a tumor suppressor gene in these tumors and a potential target for cancer diagnosis and therapy [12] [13] [14] [15] [16] [17] . However, there is no evidence of the gene deletion or mutation that is responsible for the down-regulation of SPARCL1 in lung cancer and some other cancers [18, 19] . Therefore, the SPARCL1 gene is unlike a classical tumor suppressor gene with a mutation in one allele and a mutation or deletion in another allele. Strong SPARCL1 expression has also been observed in both tumor cells and stroma of the endometrioid adenomyfibroma. However, a weak and similar staining pattern has been observed in malignant tumor and its stroma [15] .
In an animal study, Lau et al. [20] found that SPARCL1 at both RNA transcription and protein translation levels was up-regulated in hepatocellular cancer cells compared with the normal liver tissue, and they suggest that SPARCL1 is related to tumor progression and inactivation of the SPARCL1 gene is a common event in various carcinomas. Therefore, SPARCL1 has been speculated as a tumorassociated endothelium marker associated with tumor progression. Moreover, SPARCL1 has been proven to be a multifunctional glycoprotein and involved in several processes of cancer progression. However, the exact functions of SPARCL1 in human tumor progression are not completely understood, and there is no study concerning expression of SPARCL1 and its significance in colorectal cancer.
In this study, we have examined expression of SPARCL1 protein in normal colorectal mucosa and primary and metastatic colorectal cancers and further analyzed the importance of the SPARCL1 protein expression with clinicopathological data and prognosis of the colorectal cancer patients.
Patients and methods

Patients
Expression of SPARCL1 proteins was examined in normal colorectal mucosa and primary and lymph node metastatic tumors from 164 patients with primary colorectal adenocarcinomas diagnosed at the Departments of Pathology from Linköping University Hospital, Linköping, and Vrinnevi Hospital, Norrköping, Sweden, between 1982 and 2001. The normal mucosa was taken from the distant margins of surgical specimens, which were histologically free from the cancers. Adjacent normal mucosa was the tissue adjacent to the primary tumor from the same tissue sections. The metastatic tumors were from the regional lymph nodes. All patients had locally resectable colorectal adenocarcinoma, and none of the patients received chemotherapy or radiotherapy before the surgery. All patients were followed up to 10 years. Tumor localization and Dukes stages, as well as local recurrence and complication, were reviewed from their clinical and pathological archive. Tumor growth patterns were evaluated by two pathologists and classified as expansive and infiltrative patterns based on the patterns of cancer cell growth. Tumor differentiations were graded as better and worse. All patients gave a written consent.
Immunohistochemistry assay
In this study, we attempted to clarify the role of SPARCL1 protein in tumor diagnosis, progression and prognosis by using corresponding distant normal mucosa, adjacent normal mucosa and primary and lymph node metastatic tumors. Paraffin-embedded tissue sections (3 μm thick) were deparaffinized in xylene and rehydrated in progressively decreasing concentrations of ethanol to water. Antigen retrieval was performed by cooking the tissue sections in 10-mM citrate buffer in a high-pressure cooker for 5 min. After cooling-down at room temperature, the tissue sections were washed in deionized water and then incubated in 0.3% H 2 O 2 /methanol for 10 min. Thereafter, the slides were placed in washing buffer (10-mM Tris-HCl, 0.85% NaCl, 0.1% bovine serum albumin, pH 7.4) and subjected to immunostaining. The sections were incubated with a goat polyclonal anti-SPARCL1 IgG in 1:100 dilution (R&D Systems GmbH, Wiesbaden-Nordenstadt, Germany) or normal goat IgG (DAKO Corporation, Denmark) as negative controls. The slides were then rinsed with washing buffer and incubated with anti-goat IgG HRP-conjugated (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) for 1 h at room temperature. The tissue sections were then washed in washing buffer and incubated with DABchromogen substrate mixture (DAKO). Finally, sections were slightly counter-stained with hematoxylene, dehydrated and mounted under cover slips. In order to minimize subjective bias, the staining intensity and staining patterns were separately scored by two authors (HZ and DW). The samples were scored as SPARCL1 positive expression when the total number of positive cells was more than 10% of the total cells counted regardless of the staining intensity. Otherwise, the slides were scored as negative. The sections with discrepancies were re-examined until consensus was reached.
Statistical analysis
The statistical analyses were performed with STATISTICA program (Version 9.0). The differences in frequency of SPARCL1 expression between the normal mucosa and primary and lymph node metastatic tumors were tested by the chi square or McNemar's method. The relationship between the SPARCL1 expression and clinicopathological variables was analyzed by chi square. The relationship between SPARCL1 expression and survival was tested by Cox's proportional hazard model. The Kaplan-Meier method was used to calculate survival curves. The patient survivals were further analyzed by Multivariate and Interaction methods. All p values were two sided, and p< 0.05 was considered as statistically significant.
Results
Expression of SPARCL1 protein in normal colorectal mucosa and colorectal adenocarcinomas
We examined expression of SPARCL1 protein by immunohistochemistry and found that in the matched samples from the same patients, SPARCL1 protein was negative in the distant normal colorectal mucosa (Fig. 1a) and even in adjacent mucosa (Fig. 1b) . However, SPARCL1 was strongly expressed in their primary colorectal carcinomas (Fig. 1c) and weakly expressed in their metastatic tumors in the lymph nodes (Fig. 1d) . In the primary tumors, expression of the SPARCL1 protein was stronger in the highly differentiated tumors (Fig. 2a) than those in the low differentiated ones (Fig. 2b) . We also compared the intensity and patterns of the SPARCL1 protein expression in the tumor central areas (Fig. 2c ) and invasion margins (Fig. 2d) of the primary adenocarcinomas and did not find any marked difference. Moreover, there were similar expression patterns of the SPARCL1 protein in the stroma of both normal (Fig. 2e) and tumor (Fig. 2f) samples. When the frequency of the SPARCL1 protein expression was further analyzed in the whole series, a similar expression Fig. 1 Expression of SPARCL1 protein in the normal colon mucosa, adjacent normal mucosa, primary colorectal carcinoma and lymph node metastasis from the same cancer patient. The SPARCL1 protein was negative in the normal colorectal mucosa (a) and in the adjacent colorectal mucosa (b). The SPARCL1 protein was strongly expressed in the cytoplasm of colorectal cancer cells (c) and weakly expressed in the metastatic cancer cells (d) pattern was found as in the staining expression in the matched samples. The frequency of SPARCL1 expression was 17% in the distant normal colorectal mucosa, 19% in the adjacent normal mucosa, 80% in the primary colorectal cancer and 41% in the lymph metastases (date not shown).
Expression of SPARCL1 protein and clinicopathological features of colorectal cancer patients
Associations of expression of the SPARCL1 protein in the primary colorectal carcinomas with clinicopathological features were further analyzed. The expression of SPARCL1 protein was found to be associated with Dukes' stages (p=0.005). Interestingly, the frequency of SPARCL1 expression was significantly increased from the Dukes' A to Dukes' B tumors and then decreased gradually from the Dukes' B to C and D tumors (Fig. 3) . The SPARCL1 protein was more strongly expressed in the highly differentiated tumors than the lower differentiated ones (p=0.01). However, there were no correlations with patients' gender, age, tumor location, growth patterns, tumor local recurrence and complication of the patients (p> 0.05, Table 1 ).
Expression of SPARCL1 protein and patient survival
As shown in Fig. 4 , we further analyzed the association of SPARCL1 protein expression with patients' survival and found that the patients with positive expression of the SPARCL1 protein in their primary tumors had a shorter survival after surgical treatment than those patients with SPARCL1-negative tumors (p=0.017). The difference still existed as a statistical significance even when the value was adjudged with Dukes' stage (p=0.01), tumor differentiation (p=0.047) and both together Dukes' stages and tumor differentiations (p=0.006) by Multivariate and Interaction analyses. Fig. 2 Expression of SPARCL1 protein in the primary colorectal carcinomas. SPARCL1 was positive in the highly differentiated colorectal adenocarcinoma (a) and negative in the low differentiated colorectal adenocarcinoma (b). A similar expressed pattern of SPARCL1 protein was found in both central part (c) and invasive margins (d) of the primary tumors. The SPARCL1 protein was strongly expressed in the endothelial cells of the stromal blood vessels in both normal (e) and cancer (f) stroma
Discussion
In this study, we examined the expression of SPARCL1 protein in the normal colorectal mucosa, adjacent mucosa and primary and lymph node metastatic colorectal adenocarcinomas in colorectal cancer patients and further analyzed the associations of the SPARCL1 expression with clinicopathological features in colorectal cancer patients. We found that in the same patient, SPARCL1 protein was negative in both normal colorectal mucosa and adjacent mucosa. However, the SPARCL1 protein was strongly expressed in their matched primary tumor and weakly expressed in the metastatic tumors in the local lymph nodes. These results clearly demonstrated that SPARCL1 protein was up-regulated from the normal colorectal mucosa to the primary colorectal adenocarcinoma. Since it was markedly decreased from the primary tumors to the lymph node metastases, it was believed to be an early event, and it plays an essential role during the colorectal cancer early development and progression. SPARCL1 protein might be used as a valuable biomarker for early diagnosis of colorectal cancer, and we further propose that SPARCL1 protein might function as an "oncoprotein" during early progression of colorectal cancer, as has been speculated in hepatocytal cancers [20] . SPARC (Hevin) was shown to be elevated at both mRNA and protein levels, and it plays an important role in hepatocytal cancer progression [20] . However, in a study of non-small cell lung carcinoma, SPARCL1 at mRNA levels was found to be down-regulated. Moreover, it is unlike a classical tumor suppressor gene with a deletion or mutation in one allele and a mutation in another allele. The authors suggest that the down-regulation of SPARCL1 mRNA in lung cancer may be mediated through other transacting factors [19] . SPARCL1 has been shown to inhibit cellular progression from G1 to S phase or prolong G1 phase, and it is strongly down-regulated in most malignant cells [12] . Therefore, SPARCL1 protein may play opposite roles through different mechanisms in different tumor types as either "oncogene" colorectal carcinoma or "tumor suppressor" in lung cancer.
In this study, we found that in the primary colorectal cancers, the expression of SPARCL1 protein was related to Dukes' stages. SPARCL1 expression was increased from Dukes' stages A to B and then decreased from Dukes' stages B to C and D, indicating that the [21] . Therefore, the result from this study might give an additional evidence for the clear-cut between Dukes' stages A and B. Further progression of colorectal cancer in the later stages might be involved with other genetic alterations. We found that the expression of SPARCL1 protein was related to patients' survival. Over-expression of SPARCL1 protein in the primary colorectal carcinomas indicated that the patients had a short survival. On the other hand, the patients had a better outcome when they had SPARCL1-negative tumors. The statistical significance remained even after the analyses with Multivariate and Interaction method. The result provides further evidence for the SPARCL1 protein as an "oncoprotein" in colorectal cancers involved in the early formation of colorectal carcinomas. We propose that SPARCL1 protein might be utilized as a valuable indicator for predicting patients' outcome in colorectal carcinomas.
Conclusion
SPARCL1 protein was over-expressed in the early stages of primary colorectal carcinomas. The expression of SPARCL1 in primary colorectal cancer was associated with worse prognosis for colorectal cancer patients. Months Survival probability Fig. 4 Expression of SPARCL1 in the primary colorectal cancer was positively correlated to the patients' survival. The patients with positive expression of the SPARCL1 protein had significantly worse prognosis as compared to the patients with SPARCL1-negative tumors
